Ginkgo Bioworks Holdings, Inc. (DNA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Ginkgo Bioworks Holdings, Inc. (DNA) is up 12.3% since the beginning of the year. At $9 per share, DNA is trading 46.9% below its 52-week high of $18. Investors who bought $1,000 worth of DNA shares 5 years ago would now be looking at an investment worth $24.

Ginkgo Bioworks Holdings, Inc. (DNA) has returned 12.27% so far this year and 30.86% over the past 12 months.

Based on dividend-adjusted daily data since Apr 19, 2021, DNA's average daily return is -0.11%, while the average monthly return is -3.01%.

Historically, 41% of months were positive and 59% were negative. The best month was Jun 2025 with a return of +61.9%, while the worst month was Aug 2024 at -56.0%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.

On a daily basis, DNA closed higher 45% of trading days. The best single day was Aug 29, 2023 with a return of +24.0%, while the worst single day was Feb 27, 2026 at -30.5%.

Ginkgo Bioworks Holdings, Inc. has an annualized alpha of -45.55%, beta of 2.51, and R2 of 0.19 versus S&P 500 Index. Calculated based on daily prices since April 20, 2021.

• This stock participated in 226.26% of S&P 500 Index downside but only -16.11% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.19 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

DNA ranks 53 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Ginkgo Bioworks Holdings, Inc. (DNA) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Ginkgo Bioworks Holdings, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Ginkgo Bioworks Holdings, Inc. was 99.10%, occurring on Sep 9, 2024. The portfolio has not yet recovered.

The current Ginkgo Bioworks Holdings, Inc. drawdown is 98.44%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Ginkgo Bioworks Holdings, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Ginkgo Bioworks Holdings, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.